Upcoming webinar
Signatera™ Genome:
Unlocking the next level of ultrasensitive MRD detection with phased variants
Date: Tuesday, April 14, 2026
Time: 10:00 - 11:00 AM PT
Webinar duration: 60 minutes
Registrants will receive a recording of the webinar approximately one week after the event.
The ability to detect phased variants – two or more single nucleotide variants (SNVs) co-occurring on the same DNA molecule – is redefining ultrasensitive limits of detection for minimal residual disease (MRD). Because the likelihood of these linked mutations arising by chance is extremely low, phased variants support enhanced error suppression and increase confidence in variant calls at very low allele frequencies.
Signatera™ Genome RUO now integrates PhasED-Seq™, a proprietary phased variant detection technology originally developed at Foresight Diagnostics (now part of Natera), delivering ultrasensitive MRD detection at scale to our pharmaceutical and research partners.
In this webinar Dr. Max Diehn, co-founder of Foresight Diagnostics, will provide an overview of PhasED-Seq™ technology, clinical data highlights, and promising applications. An expert Q&A session will follow.
Topics include:
- Strategies to improve MRD sensitivity: Increasing variant plex versus reducing background sequencing error and why both matter.
- Error reduction through phased variants: How PhasED-Seq™ enables confident ctDNA detection at very low allele frequency detection across multiple tumor types.
- Clinical evidence: Data demonstrating improved residual disease detection and treatment response assessment in lymphoma and solid tumors, with a focus on early-stage and perioperative settings.
Hear from our speakers:
Max Diehn, MD, PhD
Professor of Radiation Oncology
Stanford University, and Co-Founder Foresight Diagnostics (now a Natera company)
David Kurtz, MD, PhD
SVP & Chief Scientific Officer
Hematology Franchise, Natera;
Co-founder, Foresight Diagnostics
(now a Natera company)
David Shames, PhD
VP, Clinical Biomarkers & Diagnostics Partnerships
Natera
Minetta Liu, MD
Chief Medical Officer
Natera
John Simmons, PhD
Global VP, Biopharma Partnerships
Natera
Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.
13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Privacy Policy
